Log in
(Ad)
Located just 25 miles from Cleveland... is a supergreenhouse unlike anything we've ever seen. Listed at over 1.4 million sq ft, (the size of 9 full-sized Costco warehouses), this marijuana grow house is capable of producing over 341,000 pounds of weed/year! And very soon it will come online and could turn a tiny 60-cent pot company into the dominator in the white-hot weed market.

NASDAQ:IOVA - Iovance Biotherapeutics Stock Price, Forecast & News

$22.70
-0.49 (-2.11 %)
(As of 01/24/2020 06:48 AM ET)
Add
Compare
Today's Range
$22.68
Now: $22.70▼
$23.25
50-Day Range
$22.70
MA: $26.28▼
$29.41
52-Week Range
$8.26
Now: $22.70▼
$29.67
Volume714,587 shs
Average Volume1.15 million shs
Market Capitalization$2.86 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.07
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IOVA
Previous Symbol
CUSIPN/A
CIK1425205
Webhttp://www.iovance.com/
Phone650-260-7120

Debt

Debt-to-Equity Ratio0.02
Current Ratio10.61
Quick Ratio10.61

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.78 per share
Price / Book6.01

Profitability

EPS (Most Recent Fiscal Year)($1.27)
Net Income$-123,580,000.00
Net MarginsN/A
Return on Equity-40.29%
Return on Assets-37.56%

Miscellaneous

Employees88
Outstanding Shares126,190,000
Market Cap$2.86 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive IOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:IOVA Rates by TradingView

(Ad)

One of the best ways to double, if not triple your investment in 2020 will be found in tech stocks. Especially those involved with the 5G rollout, where we're still finding undervalued opportunities. In our latest special report, we detail these and other hot tech stocks that should be part of your portfolio right now.

Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics Inc (NASDAQ:IOVA) released its quarterly earnings data on Monday, November, 4th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by $0.01. View Iovance Biotherapeutics' Earnings History.

When is Iovance Biotherapeutics' next earnings date?

Iovance Biotherapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Iovance Biotherapeutics.

What price target have analysts set for IOVA?

12 brokerages have issued 1-year price targets for Iovance Biotherapeutics' stock. Their forecasts range from $27.00 to $38.00. On average, they anticipate Iovance Biotherapeutics' stock price to reach $31.73 in the next year. This suggests a possible upside of 39.8% from the stock's current price. View Analyst Price Targets for Iovance Biotherapeutics.

What is the consensus analysts' recommendation for Iovance Biotherapeutics?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iovance Biotherapeutics.

What are Wall Street analysts saying about Iovance Biotherapeutics stock?

Here are some recent quotes from research analysts about Iovance Biotherapeutics stock:
  • 1. According to Zacks Investment Research, "Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. " (1/14/2020)
  • 2. HC Wainwright analysts commented, "Our thesis on TILs stands strong. In accordance with our thesis, showing efficacy in solid tumors beyond melanoma continues to represent a game changer for Iovance and, on a broader look, we continue to view this company as a viable takeout candidate for Big Pharma. We would like to reiterate that, apart from academic-based TILs therapies such as NCI and MD Anderson, Iovance is the only biotech that is developing a commercial TIL product to treat a variety of tumors and patients using the predefined cryopreserved 22-day manufacturing strategy." (7/2/2019)
  • 3. Chardan Capital analysts commented, "We therefore expect to see a similar rate in the registration-directed Cohort 4 which is currently enrolling." (5/31/2019)

Has Iovance Biotherapeutics been receiving favorable news coverage?

News stories about IOVA stock have been trending very positive recently, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Iovance Biotherapeutics earned a news sentiment score of 3.9 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Iovance Biotherapeutics.

Are investors shorting Iovance Biotherapeutics?

Iovance Biotherapeutics saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 14,830,000 shares, a decrease of 9.5% from the December 15th total of 16,390,000 shares. Based on an average trading volume of 1,220,000 shares, the short-interest ratio is currently 12.2 days. Currently, 12.9% of the shares of the stock are sold short. View Iovance Biotherapeutics' Current Options Chain.

Who are some of Iovance Biotherapeutics' key competitors?

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Portola Pharmaceuticals (PTLA), Applied Materials (AMAT), Immunomedics (IMMU), Kadmon (KDMN), BlackRock (BLK), CA (CA), Seattle Genetics (SGEN), Bristol-Myers Squibb (BMY), Heron Therapeutics (HRTX) and Lexicon Pharmaceuticals (LXRX).

Who are Iovance Biotherapeutics' key executives?

Iovance Biotherapeutics' management team includes the folowing people:
  • Dr. Maria Fardis, CEO, Pres & Director (Age 51)
  • Mr. Timothy E. Morris, CFO, Principal Accounting Officer, Corp. Sec. & Treasurer (Age 57)
  • Dr. Frederick G. Vogt Ph.D., Esq., Gen. Counsel (Age 45)
  • Mr. Howard B. Johnson, Sr. VP of Corp. Devel., Alliance Management & Program Management (Age 59)
  • Dr. Elma S. Hawkins Ph.D., MBA, Advisor to the Board (Age 62)

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.43%), Rhenman & Partners Asset Management AB (0.38%), Tocqueville Asset Management L.P. (0.05%), Evanson Asset Management LLC (0.01%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Iovance Biotherapeutics stock include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Institutional Ownership Trends for Iovance Biotherapeutics.

Which institutional investors are selling Iovance Biotherapeutics stock?

IOVA stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Tocqueville Asset Management L.P., Rhenman & Partners Asset Management AB, Evanson Asset Management LLC and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Iovance Biotherapeutics.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $22.70.

How big of a company is Iovance Biotherapeutics?

Iovance Biotherapeutics has a market capitalization of $2.86 billion. The biotechnology company earns $-123,580,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Iovance Biotherapeutics employs 88 workers across the globe.View Additional Information About Iovance Biotherapeutics.

What is Iovance Biotherapeutics' official website?

The official website for Iovance Biotherapeutics is http://www.iovance.com/.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]


MarketBeat Community Rating for Iovance Biotherapeutics (NASDAQ IOVA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  441 (Vote Outperform)
Underperform Votes:  246 (Vote Underperform)
Total Votes:  687
MarketBeat's community ratings are surveys of what our community members think about Iovance Biotherapeutics and other stocks. Vote "Outperform" if you believe IOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/24/2020 by MarketBeat.com Staff

Featured Article: What is a stock portfolio tracker?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel